NHD Global
Growth Hormone & IGF · Source-reviewed dossier
Source-Reviewed Research Dossier
GHRP-2 is a synthetic peptide studied for growth-hormone release. It acts at the receptor used by ghrelin, a natural hormone, and affects the pituitary, a small gland near the brain. Hormone responses have also been explored in pituitary-function research. A rise in growth hormone or IGF-1 is a measurable biological response, but does not automatically mean better muscle strength, fat loss or recovery. Those outcomes need direct testing. This page describes research background; NHD material is not a finished clinical medicine.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2004 drug profile describes GHRP-2/pralmorelin names, development history and GH-secretagogue pharmacology.
A drug-development profile is not proof of this catalog material’s identity or approval status.
Read the primary studyA review summarized clinical and basic aspects of growth-hormone-releasing peptides.
Class-level pharmacology cannot be translated into an outcome claim.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
A drug-development profile is not proof of this catalog material’s identity or approval status.
View primary recordClass-level pharmacology cannot be translated into an outcome claim.
View primary recordThird-party publications selected for direct relevance.
AdisInsight profile. 2004. PMID 15230633.
Ghigo E, et al. 1997. PMID 9186261.
Concise answers for researchers comparing identity, evidence and catalog variants.
The main effect studied is a rise in growth hormone acting through the ghrelin receptor. In healthy people, GHRP-2 reliably increases blood growth-hormone levels, which is why it was tested as a diagnostic: patients with growth-hormone deficiency show a much smaller rise. One review notes that long treatment can raise IGF-1. These are hormone and diagnostic findings. They do not show body-composition, anti-aging, or exercise-performance benefits, and do not confirm that any research vial will behave the same way.
The published hormone responses come from controlled human testing. They do not establish body-composition, anti-aging, or performance outcomes. They also do not confirm the identity, purity, or quality of any research material. The key sources are a 2004 drug-development profile and a class-level review, not new experiments on this catalog material. Research materials are for research, development, and manufacturing use only.
The evidence includes human pharmacology/diagnostic work and review literature on GHRP mechanisms.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
GHRP-2 has human pharmacology data, but the best-known experiments were small and measured short-term appetite or growth-hormone responses. They do not establish body-composition, anti-aging…
Updated October 1, 2026
GHRP-2 is pralmorelin, a six-residue synthetic secretagogue containing D-amino acids and 2-naphthylalanine. Free-base identity, acetate form and peptide-equivalent content must be reported separately.
Updated October 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: G25 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
